Discovery & Preclinical Development of PN-477, Next-Generation Oral Triple-G Agonist for Obesity
4:10 pm - Wednesday 9th December 2026
- Designing a differentiated Triple-G agonist by optimizing GLP-1, GIP, and glucagon receptor potency ratios to balance tolerability, metabolic efficacy, and weight loss potential
- Applying Protagonist’s oral peptide discovery platform to engineer PN-477 as both an oral and subcutaneous candidate, overcoming traditional challenges in peptide stability, potency, and delivery
- Translating molecular design into preclinical performance through receptor pharmacology, PK profiling, and in vivo efficacy studies demonstrating robust weight-loss potential across multiple animal models
